logo

For the Inventor, By the Inventor

Nijmegen, Netherlands

Byondis B.v.


USPTO Granted Patents = 18

% Expired Patents = 11.1


Trademarks = 22

Forward Citations = 13

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Rudy Gerardus Elisabeth Coumans (9 out of 16 patents)

silverMedal Gerardus Joseph Andreas Ariaans (5 out of 8 patents)

bronzeMedal Gijsbertus Franciscus Maria Verheijden (4 out of 6 patents)

4.  Gerard Rouwendal (2 out of 2 patents)

5.  Roland Jan Arends (2 out of 2 patents)

6.  Timo Kars Van Den Berg (2 out of 9 patents)

7.  Hanke Lottie Matlung (2 out of 2 patents)

8.  Katarina Franke (2 out of 2 patents)

9.  Miranda Maria Cornelia Van Der Lee (2 out of 2 patents)

10.  Jan Schouten (2 out of 2 patents)

11.  Marion Blomenrohr (2 out of 2 patents)

12.  Patrick Gerhard Groothuis (2 out of 2 patents)

13.  Patrick Henry Beusker (1 out of 14 patents)

14.  Ronald Christiaan Elgersma (1 out of 6 patents)

15.  Wiro Michael Petrus Bernardus Menge (1 out of 4 patents)


18 patents:

1. 12350345 - Dual conjugation process for preparing antibody-drug conjugates (2025-07-08),
2. 12180552 - Site-specific conjugation of linker drugs to antibodies and resulting ADCs (2024-12-31),
3. 12180295 - Humanized anti-SIRPα antibodies (2024-12-31),
4. 12178881 - Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods (2024-12-31),
5. 11718681 - Anti-SIRP α antibodies (2023-08-08),
6. 11696958 - Dual conjugation process for preparing antibody-drug conjugates (2023-07-11),
7. 11633492 - Process for the synthesis of linker-drug vc-seco-DUBA (2023-04-25),
8. 11584801 - Anti-5T4 antibodies and antibody-drug conjugates (2023-02-21),
9. 11419944 - Non-linear self-immolative linkers and conjugates thereof (2022-08-23),
10. 11382982 - Duocarmycin ADCs showing improved in vivo antitumor activity (2022-07-12),
11. 11274159 - Anti-SIRPα antibodies (2022-03-15),
12. 11136633 - Site-specific conjugation of linker drugs to antibodies and resulting ADCS (2021-10-05),
13. 11104968 - Site-specific conjugation of linker drugs to antibodies and resulting ADCS (2021-08-31),
14. 11077204 - Compositions comprising antibody-duocarmycin drug conjugates (2021-08-03),
15. 11008400 - Anti-5T4 antibodies and antibody-drug conjugates (2021-05-18),
Company Overview
Byondis B.V. is a biopharmaceutical company based in Nijmegen, Netherlands, specializing in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The organization focuses on harnessing its proprietary technology platform to create targeted therapies that enhance the efficacy and safety of cancer treatments. Byondis is committed to advancing its research in oncology, aiming to address unmet medical needs through its cutting-edge drug development initiatives.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

18 Patents

#5 in Nijmegen

#391 in Netherlands

#34,217 in the World

Nijmegen, NL
Nijmegen, Netherlands

Byondis B.v.

Forward Citations = 13

26 inventors:

goldMedal Rudy Gerardus Elisabeth Coumans (9 out of 16 patents)

silverMedal Gerardus Joseph Andreas Ariaans (5 out of 8 patents)

bronzeMedal Gijsbertus Franciscus Maria Verheijden (4 out of 6 patents)

4.  Gerard Rouwendal (2 out of 2 patents)

5.  Roland Jan Arends (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Byondis B.v.. Retrieved from https://idiyas.com/company/byondis-b-v

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…